SEHK:3933Pharmaceuticals
United Laboratories (SEHK:3933): Evaluating a Low P/E Valuation After New China Drug Consistency Approval
United Laboratories International Holdings (SEHK:3933) just cleared a meaningful regulatory hurdle, with its subsidiary’s Cefoperazone and Sulbactam injection passing China’s consistency evaluation, reinforcing its anti infective franchise and long term growth platform.
See our latest analysis for United Laboratories International Holdings.
Despite the setback of a roughly 27 percent 3 month share price return, the stock has still delivered a strong 1 year total shareholder return near 20...